ENVERIC BIOSCIENCES, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
ENVERIC BIOSCIENCES, INC. (ENVB) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 7.50% for the 12-month period ending 2020-12-31, per its 10-K filed 2021-04-01.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2021-04-01
- ENVERIC BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2020 was 7.50%, a 27.12% increase from fiscal 2019.
- ENVERIC BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2019 was 5.90%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2020-12-31 | 7.50% 10-K · filed 2021-04-01 |
| 2019-12-31 | 5.90% 10-K · filed 2021-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |